Antisense Oligonucleotide (ASO) Deal Benchmarks in Hematology

Median Upfront

$695M

Range: $364M - $1.0B

Total Deal Value

$3.4B

Range: $2.1B - $4.7B

Royalty Rate

8.9% - 16.7%

Tiered up to 20.7%

Dev Milestones

$574M

Range: $370M - $780M

Model Your Deal

Market Analysis

Antisense Oligonucleotide (ASO) therapies in hematology have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 antisense oligonucleotide (aso) asset in hematology is $695M, with total deal values reaching $3.4B. Development milestones average $574M, while regulatory milestones contribute $684M.

The hematology antisense oligonucleotide (aso) landscape is characterized by high competitive intensity in lymphoma and myeloma with established treatment paradigms. Bispecific antibodies and next-generation cell therapies are displacing traditional chemotherapy combinations. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for antisense oligonucleotide (aso) hematology deals range from 8.9% to 16.7% at the base tier, with tiered escalation reaching 12.9%-20.7% on blockbuster sales. Commercial milestones averaging $1.5B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a antisense oligonucleotide (aso) hematology licensing deal?

Based on our analysis, Phase 2 antisense oligonucleotide (aso) licensing deals in hematology average $695M in upfront payments, with a range of $364M to $1.0B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for antisense oligonucleotide (aso) hematology transactions?

The median total deal value for Phase 2 antisense oligonucleotide (aso) assets in hematology is $3.4B, ranging from $2.1B to $4.7B. This includes development milestones ($574M), regulatory milestones ($684M), and commercial milestones ($1.5B).

What royalty rates are standard for antisense oligonucleotide (aso) deals in hematology?

Base royalty rates for antisense oligonucleotide (aso) hematology transactions range from 8.9% to 16.7%, with tiered escalations reaching 12.9%-20.7% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in antisense oligonucleotide (aso) hematology deals?

Antisense Oligonucleotide (ASO) hematology deals allocate approximately 80% of total deal value to milestones. Development milestones ($574M) make up the largest share, followed by commercial milestones ($1.5B) and regulatory milestones ($684M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Antisense Oligonucleotide (ASO) Deal Benchmarks in Hematology

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

CAR-T (Hematologic) in Hematology

Bispecific Antibody in Hematology

Antisense Oligonucleotide (ASO) in Neurology

Antisense Oligonucleotide (ASO) in Rare Disease

Ready to Calculate Your Deal Terms?